PSA Test

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

By

New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

By

The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.

New Blood Test Improves Screening for Prostate Cancer

New Blood Test Improves Screening for Prostate Cancer

By

A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.

Increased PSA after prostatectomy may not result in metastasis in some men's lifetime

Increased PSA after prostatectomy may not result in metastasis in some men's lifetime

Some patients whose PSA levels become elevated after prostatectomy may die as a result of a cause unrelated to prostate cancer.

Alternative PSA screening strategies could reduce harm

Alternative PSA screening strategies could reduce harm

Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results.

Doctors' use of informed decision-making for PSA testing varies

Doctors' use of informed decision-making for PSA testing varies

Physicians' practice styles related to informed decision-making for prostate-specific antigen (PSA) screening are linked to their personal beliefs about screening.

PSA Test Has Cut Metastatic Prostate Cancer at Presentation

PSA Test Has Cut Metastatic Prostate Cancer at Presentation

Based on pre-PSA testing era estimates, expected cases at presentation three-fold higher than observed.

Age, life expectancy influence termination of PSA screening

Age, life expectancy influence termination of PSA screening

Barriers to discontinuation of screening include patient expectations, time constraints.

Prostate Cancer Screening Does Not Reduce All-Cause Mortality

Prostate Cancer Screening Does Not Reduce All-Cause Mortality

Extended follow-up shows reduced risk of death from prostate cancer, but not overall risk of death

PSA testing and prostate cancer mortality

A striking decline in prostate cancer mortality in the US compared with the UK from 1994 to 2004 coincided with a much higher uptake of prostate specific antigen (PSA) screening in the US.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs